Cyclerion Therapeutics (NASDAQ:CYCN) Shares Down 5.5% – Should You Sell?

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN)’s share price dropped 5.5% during trading on Thursday . The company traded as low as $1.3601 and last traded at $1.37. Approximately 71,574 shares changed hands during trading, a decline of 98% from the average daily volume of 4,501,084 shares. The stock had previously closed at $1.45.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Cyclerion Therapeutics in a research note on Monday, December 22nd. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has an average rating of “Sell”.

Cyclerion Therapeutics Trading Down 0.7%

The stock’s 50 day moving average price is $1.50 and its two-hundred day moving average price is $2.06. The firm has a market capitalization of $5.34 million, a PE ratio of -1.81 and a beta of 0.96.

Cyclerion Therapeutics (NASDAQ:CYCN) last announced its quarterly earnings results on Thursday, October 30th. The company reported ($0.30) earnings per share for the quarter. The company had revenue of $0.88 million during the quarter. Cyclerion Therapeutics had a negative net margin of 77.02% and a negative return on equity of 24.61%.

Hedge Funds Weigh In On Cyclerion Therapeutics

An institutional investor recently bought a new position in Cyclerion Therapeutics stock. Two Sigma Investments LP acquired a new position in shares of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 13,293 shares of the company’s stock, valued at approximately $31,000. Two Sigma Investments LP owned 0.40% of Cyclerion Therapeutics at the end of the most recent quarter. 75.62% of the stock is owned by institutional investors.

About Cyclerion Therapeutics

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of inhibitors and stimulators of soluble guanylate cyclase (sGC), an intracellular enzyme that plays a critical role in the regulation of vascular tone, cellular proliferation and inflammation. By targeting the nitric oxide (NO)–sGC–cyclic guanosine monophosphate (cGMP) signaling pathway, Cyclerion aims to address a range of cardiometabolic, cardiovascular, pulmonary and neurological disorders with significant unmet medical need.

The company’s lead program, praliciguat, is an oral sGC stimulator investigated for indications such as diabetic nephropathy, metabolic syndrome and heart failure with preserved ejection fraction.